Catalent (NYSE:CTLT) Announces Quarterly Earnings Results

Catalent (NYSE:CTLT) issued its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18), Briefing.com reports. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the firm earned ($0.10) EPS. The company’s revenue was up 4.2% on a year-over-year basis.

Catalent Price Performance

Shares of NYSE CTLT traded up $0.07 during trading hours on Thursday, hitting $60.02. 243,869 shares of the stock were exchanged, compared to its average volume of 2,040,566. The company’s fifty day simple moving average is $60.03 and its two-hundred day simple moving average is $58.03. The company has a market cap of $10.89 billion, a PE ratio of -10.92, a price-to-earnings-growth ratio of 2.06 and a beta of 1.16. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. Catalent has a 1-year low of $32.38 and a 1-year high of $61.20.

Insider Buying and Selling at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. StockNews.com downgraded Catalent from a “hold” rating to a “sell” rating in a report on Wednesday. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. One research analyst has rated the stock with a sell rating and eight have given a hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $59.83.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.